Abstract
African trypanosomes are responsible for sleeping sickness in man and nagana in cattle, which are both tremendous health burdens in Africa. Most African trypanosome species are killed by human serum. This is due to a serum trypanolytic particle specific of some old world monkeys and great apes, an HDL subclass containing two proteins which appeared recently in mammalian evolution, apolipoprotein L1 and haptoglobin related protein. Nevertheless, two African trypanosome species, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense are able to infect humans, because they developed resistance to trypanolysis. Resistance to human serum in Trypanosoma brucei rhodesiense is due to a single gene called SRA. This mechanism of lysis-resistance is therefore an example of a natural drug-antidote system which evolved during a pathogen-host arms race. The lysis and resistance mechanisms, their molecular components as well as their mode of action are reviewed. I also discuss how components of the system would be suitable drug targets and how the system could be engineered to generate an effective synthetic drug.
Keywords: Trypanosoma brucei, trypanosome, apolipoproteinL1, haptoglobin related protein, high density lipoprotein, trypanolysis
Infectious Disorders - Drug Targets
Title: The Human Trypanolytic Factor: A Drug Shaped Naturally
Volume: 10 Issue: 4
Author(s): Luc Vanhamme
Affiliation:
Keywords: Trypanosoma brucei, trypanosome, apolipoproteinL1, haptoglobin related protein, high density lipoprotein, trypanolysis
Abstract: African trypanosomes are responsible for sleeping sickness in man and nagana in cattle, which are both tremendous health burdens in Africa. Most African trypanosome species are killed by human serum. This is due to a serum trypanolytic particle specific of some old world monkeys and great apes, an HDL subclass containing two proteins which appeared recently in mammalian evolution, apolipoprotein L1 and haptoglobin related protein. Nevertheless, two African trypanosome species, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense are able to infect humans, because they developed resistance to trypanolysis. Resistance to human serum in Trypanosoma brucei rhodesiense is due to a single gene called SRA. This mechanism of lysis-resistance is therefore an example of a natural drug-antidote system which evolved during a pathogen-host arms race. The lysis and resistance mechanisms, their molecular components as well as their mode of action are reviewed. I also discuss how components of the system would be suitable drug targets and how the system could be engineered to generate an effective synthetic drug.
Export Options
About this article
Cite this article as:
Vanhamme Luc, The Human Trypanolytic Factor: A Drug Shaped Naturally, Infectious Disorders - Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/187152610791591566
DOI https://dx.doi.org/10.2174/187152610791591566 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Current Drug Targets Thyroid Function and Obesity: From Mechanisms to the Benefits of Levothyroxine in Obese Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis of Novel Imine Stilbene Analogs Exhibiting Potent Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Current Perspectives on Novel Drug Delivery Systems and Approaches for Management of Cervical Cancer: A Comprehensive Review
Current Drug Targets Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
Anti-Cancer Agents in Medicinal Chemistry Annexins Bend Wound Edges during Plasma Membrane Repair
Current Medicinal Chemistry Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?
Current Gene Therapy Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry Bio-Activities and Syntheses Developments of Triptolides
Mini-Reviews in Organic Chemistry NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews Molecular Docking Study, Cytotoxicity, Cell Cycle Arrest and Apoptotic Induction of Novel Chalcones Incorporating Thiadiazolyl Isoquinoline in Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Kaempferol-3-<i>O</i>-Rhamnoside Inhibits the Proliferation of Jurkat Cells Through Jun Amino-Terminal Kinase Signaling
The Natural Products Journal Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) DNA Secondary Structure at Chromosomal Fragile Sites in Human Disease
Current Genomics Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Current Pharmaceutical Design Analysis of Codon Usage Patterns in the Human Papillomavirus Oncogenes
Current Bioinformatics